title: [The efficiency (cost-effectiveness) of palivizumab as prophylaxis against respiratory syncytial virus infection in premature infants with a gestational age of 32-35 weeks in Spain].
abstract: OBJECTIVE
  To evaluate the efficiency (cost-effectiveness) of palivizumab in preventing severe respiratory syncytial virus (RSV) infection in premature infants with a gestational age of 32-35 weeks (GA 32-35) and two or more risk factors (RF) in Spain.
  
  
  METHODS
  
  
  
  METHODS
  decision tree model using data from the scientific literature and the FLIP I and FLIP II studies (cohort of 326 infants with GA 32-35 and two or more RF who received palivizumab) sponsored by the Spanish Society of Neonatology. Main effectiveness measure: quality-adjusted life years (QALY) gained.
  
  
  CONCLUSIONS
  the national health service (NHS), which includes direct costs (administration of palivizumab and hospital admissions), and the societal perspective, which also includes indirect costs (the child's future lost productivity). Discount: 3 % annually for effectiveness and indirect costs. Sensitivity analysis: construction of 37 scenarios modifying variables related to effectiveness and costs.
  
  
  RESULTS
  Prophylaxis with palivizumab in premature infants with GA 32-35 and two or more RF produced an incremental cost-effectiveness ratio (ICER) of 13,849 euro/QALY from the NHS perspective, and an ICER of 4,605 euro/QALY from the societal perspective. In the sensitivity analysis, from the NHS perspective the ICER ranged from 5,351 euro/QALY (most favorable scenario) to 23,276 euro/QALY (least favorable scenario).
  
  
  CONCLUSIONS
  Palivizumab is a cost-effective therapy as prophylaxis against RSV in infants with GA 32-35 and two or more RF. Its use is efficient from the NHS perspective, since the cost of a QALY, even in the least favorable scenarios, is lower than the threshold of 30,000 Euro/QALY considered socially acceptable in Spain.
authors.affiliation: Técnicas Avanzadas de Investigación en Servicios de Salud (TAISS). Madrid. España. plazaro@taiss.com
authors.forename: P
authors.initials: P
authors.lastname: Lázaro y de Mercado
authors.forename: J
authors.initials: J
authors.lastname: Figueras Aloy
authors.forename: E
authors.initials: E
authors.lastname: Doménech Martínez
authors.forename: I
authors.initials: I
authors.lastname: Echániz Urcelay
authors.forename: R
authors.initials: R
authors.lastname: Closa Monasterolo
authors.forename: M A
authors.initials: MA
authors.lastname: Wood Wood
authors.forename: K
authors.initials: K
authors.lastname: Fitch Warner
mesh_terms: D000911:Antibodies, Monoclonal / Q000191:economics / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents / Q000191:economics / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D005865:Gestational Age; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D018803:Models, Economic; D000069455:Palivizumab; D011322:Primary Prevention; D018357:Respiratory Syncytial Virus Infections / Q000188:drug therapy / Q000191:economics / Q000517:prevention & control*; D013030:Spain
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents; D000069455:Palivizumab